耐多药肺结核治疗成功相关的药物因素:个体患者数据荟萃分析
结果显示,利奈唑胺、左氧氟沙星、碳青霉烯类、莫西沙星、贝达喹啉和氯法齐明与治疗成功正相关,利奈唑胺、左氧氟沙星、莫西沙星和贝达喹啉与死亡减少相关。
要点
- 利奈唑胺、左氧氟沙星、贝达喹啉、氯法齐明和碳青霉烯类与治疗成功正相关。
- 利奈唑胺、左氧氟沙星、莫西沙星和贝达喹啉与死亡减少显著相关。
- 初始阶段有效药物数似以5种为佳,继续阶段以4种为佳。
核心结论
- 使用利奈唑胺、 later generation fluoroquinolones( later generation fluoroquinolones)、贝达喹啉、氯法齐明和碳青霉烯类治疗耐多药肺结核可显著改善治疗结局。
主要发现
- 7346例(61%)治疗成功,1017例(8%)失败或复发,1729例(14%)死亡。
- 与失败或复发相比,治疗成功与利奈唑胺( adjusted risk difference 0·15, 95% CI 0·11 to 0·18)、左氧氟沙星(0·15, 0·13 to 0·18)、碳青霉烯类(0·14, 0·06 to 0·21)、莫西沙星(0·11, 0·08 to 0·14)、贝达喹啉(0·10, 0·05 to 0·14)和氯法齐明(0·06, 0·01 to 0·10)正相关。
- 死亡减少与利奈唑胺(-0·20, -0·23 to -0·16)、左氧氟沙星(-0·06, -0·09 to -0·04)、莫西沙星(-0·07, -0·10 to -0·04)或贝达喹啉(-0·14, -0·19 to -0·10)使用显著相关。
- 与不含任何注射药物的方案相比,阿米卡星提供 modest benefits( modest benefits),但卡那霉素和卷曲霉素与更差结局相关。
- 若存在体外耐药仍使用多数药物,治疗结局显著更差;初始阶段有效药物数似以5种为佳,继续阶段以4种为佳。
关键数值与推荐
- 治疗成功与利奈唑胺 adjusted risk difference 0·15(95% CI 0·11 to 0·18)正相关。
- 死亡减少与利奈唑胺 adjusted risk difference -0·20(95% CI -0·23 to -0·16)相关。
- 初始阶段有效药物数似以5种为佳,继续阶段以4种为佳。
临床怎么用
- 在耐多药肺结核治疗方案中,优先考虑包含利奈唑胺、 later generation fluoroquinolones( later generation fluoroquinolones)、贝达喹啉、氯法齐明和碳青霉烯类的方案。
- 避免在体外耐药的情况下使用相应药物,因其与更差治疗结局相关。
- 初始阶段使用约5种有效药物、继续阶段使用约4种有效药物可能优化治疗结局。
局限性
- 推断受数据观察性性质限制。
- 约半数特定药物的调整分析估计值异质性高(基于模拟I2方法)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis. METHODS: In this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data from eligible studies, provided by study investigators, regarding clinical characteristics, treatment, and outcomes. Using propensity score-matched generalised mixed effects logistic, or linear regression, we calculated adjusted odds ratios and adjusted risk differences for success or death during treatment, for specific drugs currently used to treat multidrug-resistant tuberculosis, as well as the number of drugs used and treatment duration. FINDINGS: Of 12 030 patients from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died. Compared with failure or relapse, treatment success was positively associated with the use of linezolid (adjusted risk difference 0·15, 95% CI 0·11 to 0·18), levofloxacin (0·15, 0·13 to 0·18), carbapenems (0·14, 0·06 to 0·21), moxifloxacin (0·11, 0·08 to 0·14), bedaquiline (0·10, 0·05 to 0·14), and clofazimine (0·06, 0·01 to 0·10). There was a significant association between reduced mortality and use of linezolid (-0·20, -0·23 to -0·16), levofloxacin (-0·06, -0·09 to -0·04), moxifloxacin (-0·07, -0·10 to -0·04), or bedaquiline (-0·14, -0·19 to -0·10). Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes. The remaining drugs were associated with slight or no improvements in outcomes. Treatment outcomes were significantly worse for most drugs if they were used despite in-vitro resistance. The optimal number of effective drugs seemed to be five in the initial phase, and four in the continuation phase. In these adjusted analyses, heterogeneity, based on a simulated I2 method, was high for approximately half the estimates for specific drugs, although relatively low for number of drugs and durations analyses. INTERPRETATION: Although inferences are limited by the observational nature of these data, treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis. These findings emphasise the need for trials to ascertain the optimal combination and duration of these drugs for treatment of this condition. FUNDING: American Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America.
引用
- Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018. PMID: 30215381. doi:10.1016/S0140-6736(18)31644-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。